HAIER BIOMEDICAL(SH:688139) Xin Lang Cai Jing·2025-10-15 22:43Core Viewpoint - The report outlines the equity change of Qingdao Haier Biomedical Co., Ltd. (referred to as "Haier Biomedical") due to an increase in shareholding by Qingdao Jiushi Investment Management Co., Ltd. through its fund Jiushi Preferred No. 1, which acquired 15,897,909 shares, representing 5% of the total share capital of the company, from August 14, 2024, to October 14, 2025 [8][15]. Group 1: Information Disclosure Obligations - The information disclosure obligations are based on the Securities Law of the People's Republic of China and related regulations, ensuring that the report covers all changes in shareholding [1]. - The information disclosure obligor confirms that the report does not contain any false records, misleading statements, or significant omissions, and assumes legal responsibility for its authenticity and completeness [2]. Group 2: Purpose and Future Plans of Equity Change - The purpose of the equity change is driven by a long-term positive outlook on the life sciences industry and recognition of Haier Biomedical's performance in governance, industry position, business capabilities, operational results, and risk management [5]. - There are currently no explicit plans or agreements for increasing or decreasing shareholding in the next 12 months, and any future changes will be disclosed in accordance with relevant laws and regulations [7]. Group 3: Details of Equity Change - From August 14, 2024, to October 14, 2025, Jiushi Preferred No. 1 increased its shareholding in Haier Biomedical by 15,897,909 shares, funded by its own capital [8]. - Following this equity change, Jiushi Preferred No. 1 has become a shareholder holding more than 5% of the company's shares [9]. Group 4: Impact on Company Control - The equity change will not alter the controlling shareholder or actual controller of Haier Biomedical [16].